



Benannt durch/Designated by  
Zentralstelle der Länder  
für Gesundheitsschutz  
bei Arzneimitteln und  
Medizinprodukten  
www.zlg.de  
ZLG-BS-244.10.08



Product Service

# EC Certificate

Full Quality Assurance System

Directive 93/42/EEC on Medical Devices (MDD), Annex II excluding (4)

(Devices in Class IIa, IIb or III)

**No. G1 058561 0034 Rev. 00**

**Manufacturer:**

**IZI Medical Products, LLC**

5 Easter Court, Suite J  
Owings Mills MD 21117  
USA

**Product Category(ies): Bone Biopsy Needle Sets, Vertebroplasty Needle Sets, Biopsy Access Needles, Breast Lesion Localization Needles, Spinal Implants and Associated Manual Surgical Instruments and Spinal Curettes, and Disposable Passive Array**

The Certification Body of TÜV SÜD Product Service GmbH declares that the aforementioned manufacturer has implemented a quality assurance system for design, manufacture and final inspection of the respective devices / device categories in accordance with MDD Annex II. This quality assurance system conforms to the requirements of this Directive and is subject to periodical surveillance. For marketing of class III devices an additional Annex II (4) certificate is mandatory. See also notes overleaf.

**Report No.:** 72150139

**Valid from:** 2020-07-08

**Valid until:** 2023-10-20

**Date,** 2020-07-08

Head of Certification/Notified Body



Benannt durch/Designated by  
Zentralstelle der Länder  
für Gesundheitsschutz  
bei Arzneimitteln und  
Medizinprodukten  
www.zlg.de  
ZLG-BS-244.10.08



Product Service

# EC Certificate

Production Quality Assurance System

Directive 93/42/EEC on Medical Devices (MDD), Annex V

(Devices in class I in sterile conditions, sterilised systems or procedure packs)

**No. G2S 058561 0031 Rev. 00**

## Manufacturer

**IZI Medical Products, LLC**

5 Easter Court, Suite J  
Owings Mills MD 21117  
USA

## Product Category(ies):

**Sterile Syringes and Imaging Markers for  
Radiology, Radiation Therapy and Surgical  
Procedures**

The Certification Body of TÜV SÜD Product Service GmbH declares that the aforementioned manufacturer has implemented a quality assurance system for manufacture in accordance with MDD Annex V. This quality assurance system covers those aspects of manufacture concerned with securing and maintaining sterile conditions of the respective devices / device categories and conforms to the requirements of this Directive. It is subject to periodical surveillance. See also notes overleaf.

**Report No.:** 72153904

**Valid from:** 2020-07-03

**Valid until:** 2024-05-26

**Date,** 2020-07-03

Head of Certification/Notified Body



IZI Medical Products, LLC  
5 Easter Court, Owings Mills, MD 21117, United States of America

October 19, 2023

**Confirmation Letter Reference: CLNB1639 - 622229**

To whom it may concern,

Confirmation of receipt of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices.

This letter confirms that, SGS Belgium NV, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number 1639 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer

IZI Medical Products, LLC  
5 Easter Court  
21117 Owings Mills  
USA  
SRN Number (if available): US-MF-000029992

Holger Rossner/ Ilumark  
Hohenlindner Str.  
11 C 85622 Feldkirchen  
Germany  
SRN Number: APP000010533

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that:

- The manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry;
- The certificates expired after 26<sup>th</sup> May 2021 by course of time and were valid at the date of their expiry neither having been suspended nor withdrawn.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3 of MDR (as amended by EU 2023/607), are shown below:

- 26<sup>th</sup> May 2026 for Class III custom-made implantable devices
- 31<sup>st</sup> December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31<sup>st</sup> December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31<sup>st</sup> December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body SGS Belgium NV 1639,



Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Device 1- Osteo-Site® Bone Biopsy Needles and Accessories (081521202OsteoSite84)	Class IIa	Bone Biopsy Needle Sets	Certificate G1 058561 0034 incl. Rev. 00 0123
Device 2- Osteo-Site® Bone Biopsy Needles and Accessories (081521202OsteoSite84)	Class IIa	Vertebroplasty Needle Sets	Certificate G1 058561 0034 incl. Rev. 00 0123
Device 3 – Quick-Core Biopsy Access Needles (081521202QuickCoreXU)	Class IIa	Biopsy Access Needles	Certificate G1 058561 0034 incl. Rev. 00 0123
Device 4 – Breast Lesion Localization Needles and Coil (081521202BLN8K)	Class IIa	Breast Lesion Localization Needles	Certificate G1 058561 0034 incl. Rev. 00 0123
Device 5 – Spherz Markers and Disposable Array (081521202SPHERZUW) eIFU)	Class Is	Disposable Passive Array	Certificate G1 058561 0034 incl. Rev. 00 0123
Device 6 – Osteo-Site® Bone Biopsy Needles and Accessories (081521202OsteoSite84)	Class IIa	Sterile Syringes	Certificate G2S 058561 0031 incl. Rev. 00 0123
Device 7 – Spherz Markers and Disposable Array (081521202SPHERZUW) eIFU)	Class Is	Imaging Markers for Radiology, Radiation Therapy and surgical Procedures	Certificate G2S 058561 0031 incl. Rev. 00 0123
Device 8 – Sterile Visicoil marker B8871WG (HIBCC)	Class IIb Specific	N/A	US19/819943472 CE1639
Device 9 – Sterile MR Visicoil (Platinum)	Class IIb Specific	N/A	US19/819943472 CE1639

Device name or Basic UDI-DI	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
B8871WG (HIBCC)			
Device 10 – Sterile Pre-Loaded Visicoil B8871WG (HIBCC)	Class IIb Specific	N/A	US19/819943472 CE1639

#### Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2023/19/10	Version 1	Initial issue